Results 171 to 180 of about 2,162,885 (288)

Interprofessional Medication Error Disclosure Training Using a Telehealth Consultation Simulation. [PDF]

open access: yesAm J Pharm Educ, 2023
Baalmann A   +8 more
europepmc   +1 more source

Identification and characterization of a gene conferring stress resistance in Escherichia coli and cyanobacteria

open access: yesFEBS Open Bio, EarlyView.
Functional screening identified PcSyn14890, a cyanobacteria‐specific protein that enhances growth and stress resistance in E. coli and Synechocystis PCC6803. Although we expected it to function as a molecular chaperone, it was unable to protect against thermal aggregation of GAPDH.
Akiyo Yamada   +7 more
wiley   +1 more source

Knowledge, Attitudes, and Behaviors of Italian Home Care Nurses: Factors Associated with Medication Error Prevention in a Nationwide Cross-Sectional Survey. [PDF]

open access: yesNurs Rep
Dionisi S   +10 more
europepmc   +1 more source

Chronobiology of Cancer: How Aging Fuels Oncogenesis at the Molecular Level

open access: yesAging and Cancer, EarlyView.
This graphical abstract illustrates the key biological pathways linking aging with cancer development and progression. In the upper left, cumulative exposure to ultraviolet radiation, toxins, and reactive oxygen species (ROS) causes DNA damage and genomic instability, whereas age‐related decline in repair mechanisms, such as ATM/ATR, BER, and NER ...
Anu Singh, Aroonima Misra, Sufian Zaheer
wiley   +1 more source

Utilization of Artificial Intelligence in Reducing the Incidence of Medication Error: A Bibliometric Analysis. [PDF]

open access: yesHealth Sci Rep
Dino MJS   +12 more
europepmc   +1 more source

Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants. ABSTRACT Objective Return of disease activity is expected when patients discontinue disease‐modifying therapy (DMT) for multiple sclerosis (MS). Some MS DMTs are associated with higher‐than‐expected disease activity (rebound) after discontinuation.
Ralf Gold   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy